Registration Dossier

Administrative data

Description of key information

Key value for chemical safety assessment

Skin sensitisation

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed (not sensitising)
Additional information:
Migrated from Short description of key information:
No sensitization was observed in a reliable local lymph node assay (LLNA) on Allantoin.

Justification for selection of skin sensitisation endpoint:
Study was conducted under GLP according to OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay).

Respiratory sensitisation

Endpoint conclusion
Endpoint conclusion:
no study available
Additional information:
Migrated from Short description of key information:
No data are available on the respiratory sensitization endpoint for Allantoin.

Justification for classification or non-classification

Based on reliable LLNA results, Allantoin does not meet the criteria for classification as a skin sensitiser according to EU Directive 67/548/EEC and Regulation 1272/2008.